医用大麻治疗妇科疼痛状况:一项系统综述
该系统综述检索了1990年1月至2021年4月的文献,纳入16项研究,评估非妊娠成年女性使用大麻素治疗妇科疼痛的状况。调查数据显示13%至27%的女性使用大麻,61%至95.5%报告疼痛缓解;所有6项前瞻性队列研究和1项棕榈酰乙醇酰胺联合用药的随机对照试验报告显著疼痛缓解,但1项脂肪酸酰胺酶抑制剂随机对照试验未显示疼痛减轻。结论受限于大麻配方、给药方式和剂量差异,无法就大麻缓解妇科疼痛作出确定性声明。
要点
- 妇科疼痛患者中大麻使用率为13%至27%,多数经口或吸入、每周多次使用。
- 61%至95.5%的使用者报告疼痛缓解,但研究间配方、给药方式和剂量差异大。
- 棕榈酰乙醇酰胺联合用药的6项前瞻性队列研究和1项随机对照试验报告显著疼痛缓解。
核心结论
- 调查数据显示多数女性报告大麻改善多种妇科疼痛状况。
- 使用棕榈酰乙醇酰胺联合用药的队列研究和1项随机对照试验报告疼痛减轻。
- 由于大麻配方、给药方式和剂量各异,无法就大麻缓解妇科疼痛作出确定性声明。
研究设计与样本
- 系统综述,检索PubMed、EMBASE、Scopus、Cochrane和ClinicalTrials.gov,限1990年1月至2021年4月发表的英文文献,排除动物研究。
- 初始检索获得5189篇文章、3822条唯一引文,59篇全文审查,16篇符合纳入标准。
- 纳入研究类型为随机对照试验、队列研究和横断面研究,对象为非妊娠成年女性使用大麻素治疗妇科疼痛状况。
- 使用Covidence系统综述软件。
- PROSPERO注册号CRD42021248057。
主要发现
- 大麻使用率范围为13%至27%。
- 多数女性经口摄入或吸入大麻,每周使用多次,四氢大麻酚(THC)和 cannabidiol(CBD)剂量分别高达70 mg和2000 mg。
- 61%至95.5%报告疼痛缓解。
- 所有6项前瞻性队列研究和1项棕榈酰乙醇酰胺联合用药的随机对照试验报告显著疼痛缓解,治疗3个月后10分视觉模拟量表平均疼痛下降3.35±1.39。
- 1项脂肪酸酰胺酶抑制剂随机对照试验未显示疼痛减轻。
局限性
- 由于大麻配方、给药方式和剂量各异,无法就大麻缓解妇科疼痛作出确定性声明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The endocannabinoid system is involved in pain perception and inflammation. Cannabis contains delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which are cannabinoids that bind to endocannabinoid system receptors. A fatty acid amide called palmitoylethanolamide (PEA) enhances endogenous cannabinoids. Given that use of medical cannabis is increasing, we sought to characterize patterns of cannabis use for gynecologic pain and its effectiveness as an analgesic. DATA SOURCES: We searched PubMed, EMBASE, Scopus, Cochrane, and ClinicalTrials.gov using terms for "woman," "cannabis," and "pain" or "pelvic pain" or "endometriosis" or "bladder pain" or "cancer." The search was restricted to English-language articles published between January 1990 and April 2021 and excluded animal studies. METHODS OF STUDY SELECTION: The initial search yielded 5,189 articles with 3,822 unique citations. Studies were included if they evaluated nonpregnant adult women who used cannabinoids for gynecologic pain conditions (eg, chronic pelvic pain, vulvodynia, endometriosis, interstitial cystitis, malignancy). Study types included were randomized controlled trials (RCTs), cohort studies, and cross-sectional studies. Covidence systematic review software was used. TABULATION, INTEGRATION, AND RESULTS: Fifty-nine studies were considered for full review, and 16 met inclusion criteria. Prevalence of cannabis use ranged from 13% to 27%. Most women ingested or inhaled cannabis and used cannabis multiple times per week, with dosages of THC and CBD up to 70 mg and 2,000 mg, respectively. Sixty-one to 95.5% reported pain relief. All six prospective cohort studies and one RCT of PEA-combination medications reported significant pain relief, and the average decrease in pain after 3 months of treatment was 3.35±1.39 on the 10-point visual analog scale. However, one fatty acid amide enzyme inhibitor RCT did not show pain reduction. CONCLUSION: Survey data showed that most women reported that cannabis improved pain from numerous gynecologic conditions. Cohort studies and an RCT using PEA-combination medications reported pain reduction. However, interpretation of the studies is limited due to varying cannabis formulations, delivery methods, and dosages that preclude a definitive statement about cannabis for gynecologic pain relief. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42021248057.
引用
- Liang AL, Gingher EL, Coleman JS, et al. Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review. Obstet Gynecol. 2022. PMID: 35104069. doi:10.1097/AOG.0000000000004656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。